Koninklijke Philips N.V.
Health technology company
of 100 · unstable trend · Some good traits but inconsistent
Standing
55/100
Raw Score
47/85
Confidence
60%
Evidence
Strong primary and regulatory evidence with some contested investigative claims
About
Philips is a globally influential Dutch health technology company whose public mission and measurable access-to-care programs are offset by major product-safety and regulatory failures, especially the Respironics recall.
Observable conduct shows real social utility and formal governance commitments, but product-quality breakdowns and repeated regulator intervention materially weaken its integrity profile.
Five Pillars
Pillar scores (0–100%)
Philips shows real public benefit and structured ethical commitments, but the record does not support strong integrity claims because serious product-safety and compliance failures were not isolated or trivial.
Goodness over time
Starts at 100 at birth, natural decay after accountability age, timeline events adjust the trajectory.
17 Criteria Scores
Individual item scores (0–5) with evidence notes
Core Worldview
Contribution to Others
Personal Discipline
Reliability
Stability Under Pressure
Timeline
Key events and documented turning points
Philips is founded in Eindhoven
Philips & Co was founded in Eindhoven by Frederik Philips and Gerard Philips, beginning the company that later evolved into Royal Philips.
→ Established the long-running institution and its industrial base.
highPhilips Respironics issues major sleep and respiratory device recall
Philips Respironics recalled CPAP, BiPAP and ventilator devices after identifying risks tied to degrading PE-PUR foam that could be inhaled or swallowed by users.
→ Triggered one of the largest medtech safety crises in Philips' recent history.
highRoy Jakobs becomes CEO during recall and restructuring period
Roy Jakobs took over as CEO in October 2022 as Philips was dealing with the Respironics recall, operational pressure and a broader reset of quality and execution.
→ Marked a leadership reset tied to recovery, restructuring and product-quality improvement.
mediumInvestigative reporting alleges Philips kept thousands of CPAP warnings from FDA
ProPublica and the Pittsburgh Post-Gazette reported that Philips had received thousands of complaint and returned-device warnings tied to foam degradation years before the recall and had not fully disclosed them to the FDA when legally required.
→ Deepened concerns that the crisis reflected not only product failure but also delayed or incomplete transparency.
highFederal court enters consent decree against Philips Respironics
A federal court entered a consent decree restricting production and sale of many new sleep and respiratory devices from several Philips Respironics facilities until remediation and quality-system requirements were met.
→ Regulators imposed rare court-backed operating constraints and patient-remediation requirements.
highPhilips reports broad access-to-care and supplier sustainability progress for 2024
Philips said its 2024 business and sustainability work improved 1.96 billion lives, reached 48% supplier spend with science-based climate targets, and continued its supplier development program toward improving one million supply-chain workers' lives by 2025.
→ Strengthened evidence for large-scale social impact claims and supplier-engagement programs.
highPhilips Foundation reports access to healthcare for 46.5 million people in 2024
Philips Foundation's 2024 annual report said it helped provide access to quality healthcare for 46.5 million people, launched 22 new projects and made five new impact investments.
→ Adds concrete philanthropic and access-to-care evidence beyond Philips' core commercial operations.
mediumFDA warning letter flags quality-system issues at additional Philips facilities
The FDA issued a warning letter to Royal Philips covering inspections at facilities in Washington, Pennsylvania and Eindhoven, citing quality-system and reporting deficiencies linked to ultrasound corrective actions.
→ Showed that quality-system risk remained a live issue even beyond the Respironics recall.
highPhilips publishes Annual Report 2025 and reports return to annual profitability
Philips published its 2025 annual report, describing EUR 18 billion in 2025 sales, approximately 64,800 employees and continued progress under CEO Roy Jakobs as the company pursued profitable growth and quality recovery.
→ Signals operational recovery, though not a clean erasure of safety and compliance failures.
mediumPressure Tests
Behavior under crisis or scrutiny
Respironics recall
2021A major safety recall hit a core respiratory-care business and exposed patients, distributors and regulators to prolonged uncertainty.
Response: Philips initiated recall actions, later agreed to court-backed remediation terms and continued testing, replacement and settlement work.
mixedConsent decree and court oversight
2024FDA and DOJ secured a consent decree that restricted production and sale of many new sleep and respiratory devices from affected facilities.
Response: Philips accepted the decree and positioned quality recovery as a strategic priority.
negativeFurther FDA warning letter
2025Additional FDA quality-system findings at other Philips facilities suggested the company was still vulnerable to control failures outside the recall context.
Response: Philips said it took the warning seriously and filed a formal response.
negativeProgression
crisis years
The Respironics recall and subsequent investigations showed deep quality, remediation and disclosure strain.
decliningcurrent stage
Operational recovery is visible, but the institution is still being judged against unresolved trust and quality questions.
unstableearly years
Industrial expansion built a long-lived multinational technology institution.
improvinggrowth years
Over the last decade Philips repositioned itself as a focused health technology company with more explicit purpose and ESG framing.
improvingBehavioral Patterns
Positive
- • Consistent public purpose centered on health and well-being
- • Repeated formal reporting on human rights, supplier sustainability and governance
- • Meaningful access-to-care programs through both core business and foundation activity
Concerns
- • Patient-safety and quality problems escalated into prolonged regulatory intervention
- • Transparency and reporting questions amplified the seriousness of the Respironics crisis
- • Recovery steps are real but have not fully removed evidence of control weakness
Evidence Quality
8
Strong
3
Medium
0
Weak
Overall: strong primary and regulatory evidence with some contested investigative claims
This profile measures observable institutional behavior and public evidence, not hidden intent.